Thus, patients with EGFR mutations may benefit from a combination of anti-tumor immunologic therapy and an EGFR inhibitor, especially TKI-resistant individuals, although the causal relationship between TILs and EGFR mutations needs further evaluation. The gene discussed is EGFR; the disease is neoplasm.